- Specialty Pharmacy List
- CAP Patient Enrollment Form
- Altera® Nebulizer System Instructions for Use
- Altera® Nebulizer System Instructions for Use en Español
Statistically significant improvements in respiratory symptoms were seen in both adult and pediatric patients
Improvements were substantially smaller in adult patients but still statistically significant. Two weeks after completion of treatment, a difference in respiratory symptoms between treatment groups was still present, though the difference was smaller.
Click here to review full study design
Safety and effectiveness have not been established in pediatric patients below the age of 7 years, patients with FEV1 <25% or >75% predicted, or patients colonized with Burkholderia cepacia.
Improvements in FEV1 were comparable across adult and pediatric patients on Day 28 of treatment4
Two weeks after completion of drug treatment, the difference in FEV1 between CAYSTON and placebo groups continued but decreased to 6% (95% CI: 2%, 9%).